

Effects of the Oral Direct Renin Inhibitor Aliskiren in Pa Failure

Circulation: Heart Failure

1, 17-24

DOI: [10.1161/circheartfailure.107.740704](https://doi.org/10.1161/circheartfailure.107.740704)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. <i>Advances in Therapy</i> , 2008, 25, 1288-1302. | 1.3 | 35 |
| 2 | Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren. <i>Clinical Pharmacokinetics</i> , 2008, 47, 515-531. | 1.6 | 134 |
| 3 | The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1671-1678. | 1.2 | 5 |
| 4 | Hyperkalemia Risk and Treatment of Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 455-464. | 1.0 | 3 |
| 5 | Aldosterone Blockade in Patients with Chronic Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 15-21. | 0.9 | 9 |
| 6 | Role of renin in heart failure and therapeutic potential of direct renin inhibition. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 177-180. | 1.0 | 13 |
| 7 | Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 184-185. | 1.0 | 0 |
| 8 | Aliskiren Improves Nitric Oxide Bioavailability and Limits Atherosclerosis. <i>Hypertension</i> , 2008, 52, 467-469. | 1.3 | 8 |
| 9 | The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 971-981. | 1.0 | 76 |
| 10 | Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension. <i>Clinical Interventions in Aging</i> , 2009, 4, 137. | 1.3 | 6 |
| 11 | Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. <i>Vascular Health and Risk Management</i> , 2009, 5, 453. | 1.0 | 28 |
| 12 | Good News from Aliskiren?. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2862. | 0.1 | 0 |
| 13 | Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?. <i>Pharmaceuticals</i> , 2009, 2, 118-124. | 1.7 | 3 |
| 14 | Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase-Deficient Mice. <i>Hypertension</i> , 2009, 54, 633-638. | 1.3 | 60 |
| 15 | RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. <i>Heart</i> , 2009, 95, 1205-1208. | 1.2 | 6 |
| 16 | Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040. | 1.0 | 46 |
| 17 | Managing cardiovascular and renal risk: the potential of direct renin inhibition. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 65-76. | 1.0 | 53 |
| 18 | Overview of emerging pharmacotherapy in chronic heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2055-2074. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1685-1691. | 2.2 | 31 |
| 20 | Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1663-1671. | 0.4 | 286 |
| 21 | Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. <i>Future Cardiology</i> , 2009, 5, 453-465. | 0.5 | 5 |
| 22 | Aliskiren: the next innovation in renin-angiotensin-aldosterone system blockade. <i>Aging Health</i> , 2009, 5, 269-279. | 0.3 | 4 |
| 23 | Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. <i>Heart</i> , 2009, 95, 1920-1924. | 1.2 | 29 |
| 24 | The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. <i>Biochemical Pharmacology</i> , 2009, 78, 933-940. | 2.0 | 54 |
| 25 | Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 317-326. | 1.3 | 17 |
| 26 | Update on renin-angiotensin-aldosterone blockade in heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 455-466. | 0.4 | 1 |
| 27 | Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. <i>Current Heart Failure Reports</i> , 2009, 6, 112-116. | 1.3 | 2 |
| 28 | Direct renin inhibition: An update. <i>Current Hypertension Reports</i> , 2009, 11, 456-462. | 1.5 | 13 |
| 29 | Aliskiren and Its Rapidly, Evolving Role in the Management of Cardio-Thoracic Diseases. <i>Heart Lung and Circulation</i> , 2009, 18, 372. | 0.2 | 0 |
| 30 | ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 2287-2301. | 0.9 | 29 |
| 31 | Recent changes in the landscape of combination RAS blockade. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1373-1384. | 0.6 | 24 |
| 32 | Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. <i>Journal of Hypertension</i> , 2009, 27, 2321-2331. | 0.3 | 27 |
| 33 | Is there a role for direct renin inhibitors in chronic kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 397-403. | 1.0 | 10 |
| 34 | Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. <i>Critical Pathways in Cardiology</i> , 2009, 8, 146-150. | 0.2 | 26 |
| 36 | More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. <i>Journal of Hypertension</i> , 2010, 28, 1382-1383. | 0.3 | 0 |
| 37 | How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010, 28, 1595-1598. | 0.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 38 | Direct Renin Inhibitors as Antihypertensive Agents. American Journal of Therapeutics, 2010, 17, 237-254. | 0.5 | 13 |
| 39 | Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension, 2010, 19, 140-152. | 1.0 | 27 |
| 40 | Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. Journal of Hypertension, 2010, 28, 2145-2155. | 0.3 | 48 |
| 41 | New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren. Journal of Pharmacological Sciences, 2010, 113, 296-300. | 1.1 | 21 |
| 42 | New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Questions Remain Unsolved. Journal of Pharmacological Sciences, 2010, 113, 292-295. | 1.1 | 8 |
| 43 | New class of agents for treatment of hypertension: Focus on direct renin inhibition. Vascular Health and Risk Management, 2010, 6, 869. | 1.0 | 18 |
| 45 | The Future of Pharmacological Therapy for Heart Failure. Circulation Journal, 2010, 74, 809-817. | 0.7 | 36 |
| 47 | Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. Clinical Cardiology, 2010, 33, 536-541. | 0.7 | 13 |
| 49 | Is There a Place on the Shelf for Aliskiren?. Current Cardiovascular Risk Reports, 2010, 4, 264-270. | 0.8 | 0 |
| 50 | Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports, 2010, 12, 450-463. | 1.3 | 7 |
| 51 | New Therapeutic Approaches to Resistant Hypertension. Current Hypertension Reports, 2010, 12, 296-302. | 1.5 | 12 |
| 52 | Role of the Renin-Angiotensin System in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2010, 24, 341-344. | 1.3 | 25 |
| 53 | Application of Direct Renin Inhibition to Chronic Kidney Disease. Cardiovascular Drugs and Therapy, 2010, 24, 139-149. | 1.3 | 33 |
| 55 | Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. Journal of Clinical Hypertension, 2010, 12, 765-775. | 1.0 | 52 |
| 56 | Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vascular Health and Risk Management, 2010, 6, 549. | 1.0 | 35 |
| 57 | First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integrated Blood Pressure Control, 2010, 3, 163. | 0.4 | 4 |
| 58 | Aliskiren and valsartan combination therapy for the management of hypertension. Vascular Health and Risk Management, 2010, 6, 711. | 1.0 | 14 |
| 59 | Tratamento da insuficiência cardíaca com fração de ejeção normal. Arquivos Brasileiros De Cardiologia, 2010, 94, 414-426. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 60 | Novel neurohormonal insights with therapeutic potential in chronic heart failure. <i>Future Cardiology</i> , 2010, 6, 361-372. | 0.5 | 2 |
| 61 | Implications of Recently Published Trials of Blood Pressure-“Lowering Drugs in Hypertensive or High-Risk Patients. <i>Hypertension</i> , 2010, 55, 819-831. | 1.3 | 44 |
| 62 | Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?. <i>Future Cardiology</i> , 2010, 6, 129-135. | 0.5 | 4 |
| 63 | Aliskiren versus ramipril in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 193-200. | 1.0 | 23 |
| 64 | Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 531-548. | 2.2 | 196 |
| 66 | Is there a future for direct renin inhibitors?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 653-661. | 1.9 | 3 |
| 67 | The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?. <i>Hypertension Research</i> , 2010, 33, 4-10. | 1.5 | 40 |
| 68 | HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure-“lessons learnt from a decade of trials. <i>European Journal of Heart Failure</i> , 2010, 12, 99-103. | 2.9 | 5 |
| 69 | A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F929-F941. | 1.3 | 54 |
| 70 | Aliskiren: A novel, orally active renin inhibitor. <i>Systematic Reviews in Pharmacy (discontinued)</i> , 2010, 1, 93. | 0.6 | 5 |
| 71 | Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1330-1339. | 2.2 | 51 |
| 72 | Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. <i>European Heart Journal</i> , 2010, 31, 1993-2005. | 1.0 | 54 |
| 73 | Blood Pressure and Diabetic Nephropathy. <i>Diabetes Care</i> , 2010, 33, e30-e35. | 4.3 | 7 |
| 74 | Applications of “decisionable”™ biomarkers in cardiovascular drug development. <i>Biomarkers in Medicine</i> , 2010, 4, 815-827. | 0.6 | 4 |
| 75 | Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. <i>Hypertension Research</i> , 2010, 33, 62-66. | 1.5 | 24 |
| 76 | Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition. <i>Postgraduate Medicine</i> , 2010, 122, 203-212. | 0.9 | 7 |
| 77 | Usefulness of direct renin inhibition with aliskiren as antihypertensive treatment. <i>Hipertension Y Riesgo Vascular</i> , 2010, 27, 245-248. | 0.3 | 2 |
| 78 | Aliskiren. <i>Drugs</i> , 2010, 70, 2011-2049. | 4.9 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 79 | Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. <i>Drugs</i> , 2010, 70, 1215-1230. | 4.9 | 37 |
| 80 | Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: Antihypertensive effects and benefits beyond BP control. <i>Life Sciences</i> , 2010, 86, 289-299. | 2.0 | 39 |
| 81 | Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010, 16, 964-970. | 0.7 | 62 |
| 83 | THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 97-105. | 0.6 | 3 |
| 85 | The evolution of angiotensin blockade in the management of cardiovascular disease. <i>Canadian Journal of Cardiology</i> , 2010, 26, 7E-13E. | 0.8 | 10 |
| 86 | The Effects of Heart Failure on Renal Function. <i>Cardiology Clinics</i> , 2010, 28, 453-465. | 0.9 | 26 |
| 87 | ARBs and ACEIs together in the treatment of hypertension and its complications? current practical recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2619-2623. | 0.9 | 3 |
| 89 | Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 359-373. | 1.0 | 8 |
| 90 | Aliskiren in the Management of Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 349-358. | 1.0 | 12 |
| 91 | The Role of Direct Renin Inhibition in Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 303-315. | 1.0 | 6 |
| 92 | Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 755-764. | 2.9 | 19 |
| 93 | Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 137-156. | 0.9 | 40 |
| 94 | Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 115-128. | 1.5 | 10 |
| 95 | Biomarkers as Surrogate End Points in Heart Failure Trials. <i>Heart Failure Clinics</i> , 2011, 7, 501-507. | 1.0 | 7 |
| 96 | The Month After. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1967-1969. | 1.2 | 0 |
| 99 | Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 153-171. | 1.0 | 65 |
| 101 | Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. <i>American Journal of Medicine</i> , 2011, 124, 15-19. | 0.6 | 17 |
| 102 | p90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: A pathogenic mechanism for ischemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 272-275. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 103 | Aldosterone Antagonists in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 150-159. | 1.0 | 13 |
| 104 | Optimal renin-angiotensin-aldosterone system control—direct renin inhibitors beyond blood pressure reductions. <i>Journal of Indian College of Cardiology</i> , 2011, 1, 108-111. | 0.1 | 0 |
| 105 | Novel therapeutic targets for the treatment of heart failure. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 536-555. | 21.5 | 125 |
| 106 | Medical therapy for chronic heart failure. <i>Lancet, The</i> , 2011, 378, 713-721. | 6.3 | 73 |
| 107 | Role of aliskiren in blood pressure control and renoprotection. <i>International Journal of Nephrology and Renovascular Disease</i> , 2011, 4, 41. | 0.8 | 10 |
| 108 | A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. <i>Vascular Health and Risk Management</i> , 2011, 7, 297. | 1.0 | 20 |
| 109 | Potential Benefits of Aliskiren Beyond Blood Pressure Reduction. <i>Cardiology in Review</i> , 2011, 19, 90-94. | 0.6 | 4 |
| 110 | Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. <i>Journal of Clinical Hypertension</i> , 2011, 13, 506-516. | 1.0 | 23 |
| 111 | Renin Inhibitors. <i>Journal of Clinical Hypertension</i> , 2011, 13, 662-666. | 1.0 | 9 |
| 112 | Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. <i>Journal of Clinical Hypertension</i> , 2011, 13, 848-855. | 1.0 | 4 |
| 113 | Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. <i>American Journal of Kidney Diseases</i> , 2011, 57, 760-772. | 2.1 | 14 |
| 115 | Inhibición directa de la renina y protección de órganos diana. Más allá del descenso de la presión. <i>Revista Española De Cardiología Suplementos</i> , 2011, 11, 18-24. | 0.2 | 0 |
| 117 | Prognostic Value of Plasma Renin Activity in Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 246-251. | 0.7 | 61 |
| 118 | Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 87-97. | 1.3 | 9 |
| 119 | Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 315-321. | 1.3 | 6 |
| 120 | Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. <i>Basic Research in Cardiology</i> , 2011, 106, 979-993. | 2.5 | 24 |
| 121 | Role of RAAS Inhibition in the Prevention of Cardiovascular Disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 279-288. | 0.4 | 6 |
| 122 | Knocking Out Angiotensin II in the Heart. <i>Current Hypertension Reports</i> , 2011, 13, 129-135. | 1.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 123 | Less RAAS is more, or not. Expert Review of Cardiovascular Therapy, 2011, 9, 1363-1365. | 0.6 | 2 |
| 124 | Reducing Cardiovascular Events and End-Organ Damage in Patients with Hypertension: New Considerations. Postgraduate Medicine, 2011, 123, 7-17. | 0.9 | 3 |
| 126 | Direct Renin Inhibition. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 93-105. | 1.0 | 18 |
| 127 | Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106. | 2.9 | 68 |
| 128 | Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure, 2011, 13, 107-114. | 2.9 | 113 |
| 129 | Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 746-754. | 2.9 | 30 |
| 130 | Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice With Chronic Cerebral Hypoperfusion. Hypertension, 2011, 58, 635-642. | 1.3 | 93 |
| 131 | Direct renin inhibition: update on clinical investigations with aliskiren. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 424-437. | 3.1 | 1 |
| 132 | Rationale for the use of multiple blockers of the renin-angiotensin-aldosterone system in specific patient populations. Therapy: Open Access in Clinical Medicine, 2011, 8, 227-236. | 0.2 | 3 |
| 133 | Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 2011, 32, 1227-1234. | 1.0 | 130 |
| 134 | Advances in the Epidemiology of Heart Failure and Left Ventricular Remodeling. Circulation, 2011, 124, e516-9. | 1.6 | 62 |
| 135 | Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Therapeutic Advances in Cardiovascular Disease, 2011, 5, 169-178. | 1.0 | 2 |
| 136 | Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 569-577. | 1.6 | 219 |
| 137 | Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. Circulation Research, 2011, 109, 437-452. | 2.0 | 56 |
| 138 | Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. CardioRenal Medicine, 2011, 1, 53-66. | 0.7 | 9 |
| 139 | Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal, 2011, 32, 2135-2142. | 1.0 | 74 |
| 140 | Effects of Aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertension Research, 2011, 34, 308-313. | 1.5 | 43 |
| 141 | Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. Expert Review of Cardiovascular Therapy, 2011, 9, 421-427. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 142 | Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. <i>European Heart Journal</i> , 2011, 32, 2642-2649. | 1.0 | 56 |
| 143 | Limitations of angiotensin inhibition. <i>Nature Reviews Nephrology</i> , 2011, 7, 356-359. | 4.1 | 27 |
| 144 | Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 409-412. | 1.0 | 22 |
| 145 | The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e42-e42. | 2.4 | 105 |
| 146 | Clinical Role of Direct Renin Inhibition in Hypertension. <i>American Journal of Therapeutics</i> , 2012, 19, 204-210. | 0.5 | 12 |
| 147 | Aliskiren Alone or in Combination for the Treatment of Mild-to-Moderate Hypertension: Current Role and Future Perspectives. <i>Journal of Pharmacy Technology</i> , 2012, 28, 16-25. | 0.5 | 0 |
| 148 | Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions. <i>Current Drug Safety</i> , 2012, 7, 76-85. | 0.3 | 20 |
| 149 | Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012, 14, 341-343. | 2.9 | 737 |
| 150 | Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. <i>Hypertension Research</i> , 2012, 35, 62-69. | 1.5 | 19 |
| 152 | Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 258-264. | 2.2 | 11 |
| 153 | Haemodynamic effects of aliskiren in decompensated severe heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 128-132. | 1.0 | 4 |
| 154 | How full is our antihypertensives pipeline?. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 7. | 0.2 | 1 |
| 155 | Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. <i>CardioRenal Medicine</i> , 2012, 2, 281-297. | 0.7 | 18 |
| 156 | Effects of Aliskiren on Blood Pressure and Myocardial Function Assessed by Global Longitudinal Strain in Patients with Arterial Hypertension and Diastolic Dysfunction. <i>Folia Medica</i> , 2012, 54, 30-34. | 0.2 | 7 |
| 157 | Editorial [Hot Topic: Current Topics on the Epidemiology, Pathogenesis, and Treatment of Diabetes Mellitus and its Complications (Guest Editors: Moses S. Elisaf and Evangelos C. Rizos)]. <i>Current Vascular Pharmacology</i> , 2012, 10, 138-139. | 0.8 | 0 |
| 158 | Lipids and Non-Cardiac Vascular Disease: A Lecture Overview. <i>Current Vascular Pharmacology</i> , 2012, 10, 743-744. | 0.8 | 3 |
| 159 | Combinations of Renin-Angiotensin-Aldosterone System Antagonists: True Advantages?. <i>Current Pharmaceutical Design</i> , 2012, 18, 952-957. | 0.9 | 2 |
| 160 | Aliskiren Improves Left Ventricular Dysfunction and Reduces Cardiac Dilation in Syrian Cardiomyopathic Hamsters. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 547-552. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 161 | Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. <i>Journal of Hypertension</i> , 2012, 30, 107-116. | 0.3 | 27 |
| 163 | Contemporary Medical Management of Systolic Heart Failure. <i>Circulation Journal</i> , 2012, 76, 268-277. | 0.7 | 24 |
| 164 | Effect of Direct Renin Inhibitor, Aliskiren, on Peripheral Blood Monocyte Subsets and Myocardial Salvage in Patients With Primary Acute Myocardial Infarction. <i>Circulation Journal</i> , 2012, 76, 1461-1468. | 0.7 | 7 |
| 165 | Does Direct Inhibition Bring Direct Benefit?. <i>Circulation Journal</i> , 2012, 76, 1326. | 0.7 | 0 |
| 166 | Novel Treatments for Cardiovascular Disease Prevention. <i>Cardiovascular Therapeutics</i> , 2012, 30, 257-263. | 1.1 | 12 |
| 167 | Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213. | 13.9 | 1,145 |
| 169 | Renin activates PI3KÁAktÊNOS signalling through the angiotensin AT₁ and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii. <i>British Journal of Pharmacology</i> , 2012, 166, 2024-2035. | 2.7 | 35 |
| 170 | Heart Failure in Hypertension. <i>Drugs</i> , 2012, 72, 1373-1398. | 4.9 | 16 |
| 171 | Inhibition of renin and the (pro)renin receptor system. <i>Blood Pressure</i> , 2012, 21, 377-385. | 0.7 | 1 |
| 172 | Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function. <i>Medical Hypotheses</i> , 2012, 79, 448-451. | 0.8 | 1 |
| 173 | The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and—beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 713-725. | 0.6 | 10 |
| 175 | Managing the Kidney when the Heart is Failing. , 2012, , . | | 0 |
| 176 | Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]. <i>Current Vascular Pharmacology</i> , 2012, 10, 745-747. | 0.8 | 1 |
| 177 | Mensagem do Editor. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 99, 575-575. | 0.3 | 32 |
| 178 | Aliskiren suppresses the renin–angiotensin–aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension. <i>International Journal of Nephrology and Renovascular Disease</i> , 2012, 5, 125. | 0.8 | 2 |
| 179 | Cardiomyocyte and Heart Failure. , 2012, , . | | 1 |
| 180 | Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 131-143. | 1.3 | 10 |
| 181 | New roles for renin and prorenin in heart failure and cardiorenal crosstalk. <i>Heart Failure Reviews</i> , 2012, 17, 191-201. | 1.7 | 64 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 182 | The Neurohormonal Network in the RAAS Can Bend Before Breaking. <i>Current Heart Failure Reports</i> , 2012, 9, 81-91. | 1.3 | 9 |
| 183 | Aliskiren-associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 333-336. | 0.7 | 7 |
| 184 | Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. <i>International Journal of Clinical Practice</i> , 2012, 66, 251-261. | 0.8 | 13 |
| 185 | How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. <i>Cellular Signalling</i> , 2012, 24, 1583-1591. | 1.7 | 13 |
| 186 | Combined Blockade of the Renin System: An Example of Hormesis. <i>Journal of Clinical Hypertension</i> , 2012, 14, 573-574. | 1.0 | 0 |
| 187 | Novel therapies in acute and chronic heart failure. , 2012, 135, 1-17. | | 45 |
| 188 | Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 470-481. | 1.2 | 5 |
| 189 | Review of Vasodilators in Acute Decompensated Heart Failure: The Old and the New. <i>Journal of Cardiac Failure</i> , 2013, 19, 478-493. | 0.7 | 28 |
| 190 | Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?. <i>Cardiovascular Diabetology</i> , 2013, 12, 108. | 2.7 | 9 |
| 191 | Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure. <i>Current Cardiology Reports</i> , 2013, 15, 329. | 1.3 | 4 |
| 192 | Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. <i>Heart and Vessels</i> , 2013, 28, 442-452. | 0.5 | 7 |
| 193 | Almanac 2013: heart failure. <i>Heart</i> , 2013, 99, 1562-1566. | 1.2 | 4 |
| 194 | Pathological Ventricular Remodeling. <i>Circulation</i> , 2013, 128, 1021-1030. | 1.6 | 126 |
| 195 | Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPSâ€“UHPLCâ€“MS/MS for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 938, 86-95. | 1.2 | 33 |
| 196 | The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1041-1047. | 1.9 | 23 |
| 197 | When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?. <i>Congestive Heart Failure</i> , 2013, 19, 107-115. | 2.0 | 25 |
| 198 | The past, present and future of reninâ€“angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687. | 0.8 | 97 |
| 199 | Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. <i>Cardiovascular Therapeutics</i> , 2013, 31, 84-91. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 200 | Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. <i>Molecular and Cellular Biochemistry</i> , 2013, 373, 189-194. | 1.4 | 36 |
| 201 | Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 125-134. | 6.1 | 78 |
| 202 | Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125. | 3.8 | 297 |
| 203 | An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 847-858. | 1.5 | 6 |
| 204 | Aliskiren inhibits experimental venous thrombosis in two-kidney one-clip hypertensive rats. <i>Thrombosis Research</i> , 2013, 131, e39-e44. | 0.8 | 4 |
| 205 | It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 133-138. | 1.3 | 8 |
| 206 | Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 145-153. | 1.3 | 24 |
| 207 | Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2013, 15, 1205-1207. | 2.9 | 5 |
| 208 | Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, C18-C22. | 0.2 | 2 |
| 209 | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. <i>BMJ, The</i> , 2013, 346, f360-f360. | 3.0 | 185 |
| 210 | Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 232-241. | 1.1 | 30 |
| 211 | Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2013, , 241-269. | | 1 |
| 212 | Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. <i>Hepatology Research</i> , 2013, 43, 1241-1250. | 1.8 | 25 |
| 213 | Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 427-432. | 1.0 | 3 |
| 214 | Direct renin inhibition: extricating facts from fables. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 153-167. | 1.0 | 3 |
| 215 | Angiotensin II and Oxidative Stress in the Failing Heart. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1095-1109. | 2.5 | 93 |
| 216 | Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. <i>Hypertension Research</i> , 2013, 36, 252-261. | 1.5 | 25 |
| 217 | Review of direct renin inhibition by aliskiren. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 193-196. | 1.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 218 | Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). <i>Circulation Journal</i> , 2013, 77, 231-248. | 0.7 | 82 |
| 219 | Hipertensão arterial sistãmica primãria. <i>Medicina</i> , 2013, 46, 256-272. | 0.0 | 5 |
| 220 | Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. <i>BioMed Research International</i> , 2014, 2014, 1-21. | 0.9 | 107 |
| 222 | Effect of Direct Renin Inhibitor on Left Ventricular Remodeling in Patients With Primary Acute Myocardial Infarction. <i>International Heart Journal</i> , 2014, 55, 17-21. | 0.5 | 5 |
| 223 | Current treatments for acute heart failure: focus on serelaxin. <i>Research Reports in Clinical Cardiology</i> , 2014, , 169. | 0.2 | 1 |
| 224 | Almanac 2013: heart failure. <i>Anatolian Journal of Cardiology</i> , 2014, 14, 313-318. | 0.4 | 0 |
| 225 | Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists. <i>Clinical and Experimental Hypertension</i> , 2014, 36, 497-502. | 0.5 | 5 |
| 226 | Heart failure highlights in 2012â2013. <i>European Journal of Heart Failure</i> , 2014, 16, 122-132. | 2.9 | 11 |
| 227 | Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing ReninâAngiotensinâAldosterone System Antagonists. <i>American Journal of Therapeutics</i> , 2014, 21, 419-435. | 0.5 | 8 |
| 228 | Direct Renin Inhibitor Induced Renal Failure. <i>American Journal of Therapeutics</i> , 2014, 21, e53-e55. | 0.5 | 3 |
| 229 | Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 821-830. | 0.7 | 6 |
| 230 | Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , 2014, 35, 16-24. | 1.0 | 159 |
| 231 | Antihypertensive effect of caffeic acid and its analogs through dual reninâangiotensinâaldosterone system inhibition. <i>European Journal of Pharmacology</i> , 2014, 730, 125-132. | 1.7 | 69 |
| 232 | The Renin-Angiotensin-Aldosterone System and Heart Failure. <i>Cardiology Clinics</i> , 2014, 32, 21-32. | 0.9 | 139 |
| 233 | Novel drug targets in clinical development for heart failure. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 765-774. | 0.8 | 22 |
| 234 | ReninâAngiotensin System Blocking Drugs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 14-33. | 1.0 | 53 |
| 235 | State of the art paper Aliskiren â an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. <i>Archives of Medical Science</i> , 2014, 4, 830-836. | 0.4 | 6 |
| 236 | <i>Esc. Acta Cardiologica</i> , 2014, 69, 341-347. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 238 | Effect of aliskiren on vascular remodelling in small retinal circulation. <i>Journal of Hypertension</i> , 2015, 33, 2491-2499. | 0.3 | 13 |
| 239 | A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness. <i>Journal of Drug Metabolism & Toxicology</i> , 2015, 06, . | 0.1 | 0 |
| 240 | Fluid Management In Patients With Chronic Heart Failure. <i>Cardiac Failure Review</i> , 2015, 1, 90. | 1.2 | 56 |
| 241 | Can Aliskiren be Considered as a New Novel Drug for Hypertension?. <i>Cureus</i> , 2015, 7, e375. | 0.2 | 1 |
| 242 | Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 126-131. | 1.4 | 13 |
| 243 | Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) <i>Tj ETQq1 1 0.784314.rgBT /Overlock 10</i> <i>Heart Journal</i> . 2015. 169. 693-701.e3. | 1.2 | 16 |
| 244 | Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806. | | 2 |
| 245 | Effects Of The Direct Renin Inhibitor Aliskiren On Oxidative Stress In Isolated Rat Heart. <i>Serbian Journal of Experimental and Clinical Research</i> , 2015, 16, 193-199. | 0.2 | 0 |
| 246 | Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E435-E449. | 1.8 | 91 |
| 247 | Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831. | 1.6 | 34 |
| 248 | Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 956-964. | 1.0 | 9 |
| 249 | Combination therapy in chronic kidney disease?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 147-152. | 1.0 | 3 |
| 250 | Role of the Renin-Angiotensin-Aldosterone System in the Management of Neonatal Heart Failure. <i>NeoReviews</i> , 2015, 16, e575-e585. | 0.4 | 2 |
| 251 | New medical therapies for heart failure. <i>Nature Reviews Cardiology</i> , 2015, 12, 730-740. | 6.1 | 43 |
| 252 | Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. <i>Clinica Chimica Acta</i> , 2015, 443, 85-93. | 0.5 | 22 |
| 253 | Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. <i>Current Hypertension Reports</i> , 2015, 17, 511. | 1.5 | 5 |
| 256 | Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 887. | 0.9 | 16 |
| 257 | The bumpy road to drug development for acute heart failure. <i>European Heart Journal Supplements</i> , 2016, 18, G19-G32. | 0.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 258 | Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532. | 13.9 | 204 |
| 259 | Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 219-228. | 0.9 | 13 |
| 260 | Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2016, 18, 70-78. | 1.0 | 9 |
| 261 | Direct Renin Inhibitor is Better than Angiotensin II Receptor Blocker for Intrarenal Arterioles. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 561-569. | 0.9 | 5 |
| 262 | The Future of Clinical Trials in Cardiovascular Medicine. <i>Circulation</i> , 2016, 133, 2662-2670. | 1.6 | 33 |
| 263 | New Targets in the Drug Treatment of Heart Failure. <i>Drugs</i> , 2016, 76, 187-201. | 4.9 | 2 |
| 264 | New Management Strategies in Heart Failure. <i>Circulation Research</i> , 2016, 118, 480-495. | 2.0 | 37 |
| 265 | Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 205, 65-71. | 0.8 | 23 |
| 266 | Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 89 |
| 267 | Successful long-term effects of direct renin inhibitor aliskiren in a patient with atherosclerotic renovascular hypertension. <i>CEN Case Reports</i> , 2017, 6, 66-73. | 0.5 | 3 |
| 268 | Aliskiren Improves Ischemia- and Oxygen Glucose Deprivation-Induced Cardiac Injury through Activation of Autophagy and AMP-Activated Protein Kinase. <i>Frontiers in Pharmacology</i> , 2017, 8, 819. | 1.6 | 11 |
| 269 | Renin Inhibition with Aliskiren: A Decade of Clinical Experience. <i>Journal of Clinical Medicine</i> , 2017, 6, 61. | 1.0 | 20 |
| 270 | Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis. <i>Oncotarget</i> , 2017, 8, 89364-89374. | 0.8 | 9 |
| 271 | Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level. <i>Hypertension Research</i> , 2018, 41, 435-443. | 1.5 | 9 |
| 272 | Renin-angiotensin system inhibition—it's been a long but fruitful journey. <i>European Journal of Heart Failure</i> , 2018, 20, 687-688. | 2.9 | 0 |
| 273 | Combination Therapy of Renin Angiotensin System Inhibitors and β -Blockers in Patients with Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1067, 17-30. | 0.8 | 7 |
| 274 | Newer hormonal pharmacotherapies for heart failure. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 35-49. | 1.2 | 1 |
| 275 | Low- and High-renin Heart Failure Phenotypes with Clinical Implications. <i>Clinical Chemistry</i> , 2018, 64, 597-608. | 1.5 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 276 | Myocardial Cell Signaling During the Transition to Heart Failure. , 2018, 9, 75-125. | | 12 |
| 277 | OBSOLETE: Neurohormonal Blockade. , 2018, , . | | 0 |
| 278 | PHARMACOTHERAPY OF HEART FAILURE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 78. | 0.3 | 2 |
| 279 | Neurohormonal Blockade. , 2018, , 459-476. | | 0 |
| 280 | TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model. PLoS ONE, 2018, 13, e0202176. | 1.1 | 6 |
| 281 | The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. American Heart Journal, 2018, 201, 164-167. | 1.2 | 5 |
| 282 | Renin Activity in Heart Failure with Reduced Systolic Functionâ€”New Insights. International Journal of Molecular Sciences, 2019, 20, 3182. | 1.8 | 31 |
| 283 | Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys. Regulatory Toxicology and Pharmacology, 2019, 109, 104484. | 1.3 | 2 |
| 284 | The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis. Journal of Human Hypertension, 2019, 33, 795-806. | 1.0 | 3 |
| 285 | Relation between therapyâ€”induced changes in natriuretic peptide levels and longâ€”term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2019, 21, 613-620. | 2.9 | 9 |
| 286 | Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. Cardiovascular Medicine, 2019, , 105-120. | 0.0 | 0 |
| 288 | Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988265. | 1.0 | 2 |
| 289 | Efficacy of aliskiren supplementation for heart failure. Herz, 2019, 44, 398-404. | 0.4 | 3 |
| 290 | The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42. | 1.7 | 52 |
| 291 | Significance of the Renin-Angiotensin System in Clinical Conditions. , 0, , . | | 6 |
| 292 | <scp>VICTORIA</scp> in context. European Journal of Heart Failure, 2020, 22, 1747-1751. | 2.9 | 2 |
| 293 | Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466. | 1.5 | 7 |
| 294 | Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. Bioorganic and Medicinal Chemistry, 2020, 28, 115466. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 295 | Efficacy of Add-on Therapy with Carvedilol and the Direct Renin Inhibitor Aliskiren for Improving Cardiac Sympathetic Nerve Activity, Cardiac Function, Symptoms, Exercise Capacity and Brain Natriuretic Peptide in Patients with Dilated Cardiomyopathy. <i>Annals of Nuclear Cardiology</i> , 2021, 7, 33-42. | 0.0 | 0 |
| 296 | Ageing and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. , 2014, , 259-289. | | 6 |
| 297 | AT1 Receptors, Angiotensin Receptor Blockade, and Clinical Hypertensive Disease. , 2009, , 59-79. | | 2 |
| 298 | Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 88189-88198. | 0.8 | 5 |
| 299 | Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 459. | 0.9 | 15 |
| 300 | Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 134-146. | 0.4 | 32 |
| 301 | Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020, 2, 113. | 0.0 | 12 |
| 302 | Aliskiren, the first direct renin inhibitor for treatment of hypertension. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 32-38. | 0.2 | 7 |
| 303 | The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade. <i>Journal of Diabetes & Metabolism</i> , 2012, 03, . | 0.2 | 13 |
| 304 | Renin and cardiovascular disease: Worn-out path, or new direction. <i>World Journal of Cardiology</i> , 2011, 3, 72. | 0.5 | 9 |
| 305 | Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. <i>Cardiology Journal</i> , 2015, 22, 5-11. | 0.5 | 9 |
| 306 | Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2007, , 331-362. | | 0 |
| 307 | Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. , 2009, , 93-102. | | 1 |
| 308 | Brno Registry - Drug therapy after myocardial infarction. <i>Cor Et Vasa</i> , 2009, 51, 128-130. | 0.1 | 1 |
| 309 | ACE inhibitors or sartans in the management of myocardial infarction survivors?. <i>Cor Et Vasa</i> , 2009, 51, 103-111. | 0.1 | 1 |
| 311 | Evidencia actual de la combinaci3n de un IDR y un ARA II/IECA. <i>Medwave</i> , 2010, 10, . | 0.2 | 0 |
| 314 | Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 81-99. | | 0 |
| 315 | Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 23-41. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 316 | Aliskiren in Patients Failing to Achieve Blood Pressure Targets With Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. <i>Cardiology Research</i> , 2012, 3, 147-153. | 0.5 | 0 |
| 317 | New Therapeutics in Hypertension. , 0, , . | | 0 |
| 318 | Comparative effects of renin-angiotensin-aldosterone system modulators on right heart function and prognosis in patients with severe systolic chronic heart failure. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2012, 11, 50-55. | 0.4 | 1 |
| 319 | New Drugs for Hypertension. , 2013, , 226-229. | | 0 |
| 320 | Renin angiotensin aldosterone system blockade in practice: A Clinical Perspective. <i>Ibnosina Journal of Medicine and Biomedical Sciences</i> , 2014, 6, 57. | 0.2 | 0 |
| 321 | Almanac 2013: Heart failure the national society journals present selected research that has driven recent advances in clinical cardiology. <i>Srce I Krvni Sudovi</i> , 2014, 33, 273-278. | 0.1 | 0 |
| 322 | Reperfusion and Vasodilator Therapy in Elderly Patients with STEMI and Heart Failure: Improving Outcomes. , 2014, , 199-220. | | 0 |
| 323 | Calcium Channel BlockersDirect Renin Inhibitors (DRI) as Novel Antihypertensive Agents. <i>Journal of the Nihon University Medical Association</i> , 2014, 73, 14-16. | 0.0 | 0 |
| 325 | How to Use Inhibitors of the Renin-Angiotensin-Aldosterone System in Patients with CKD and Heart Failure. , 2015, , 163-170. | | 0 |
| 326 | Renal Denervation for Congestive Heart Failure. , 2015, , 163-173. | | 0 |
| 327 | Renal dysfunction in patients with cardiovascular disease. The effects of blockers of the renin-angiotensinaldosterone system. <i>Cardiosomatics</i> , 2016, 7, 59-64. | 0.2 | 0 |
| 328 | THREE- AND SIX-MONTH EXPERIENCE OF EPLERENONE USE IN PATIENTS WITH ISCHEMIC DILATION CARDIOPATHY WITHOUT SIGNS OF DECOMPENSATION. <i>Siberian Medical Review</i> , 2017, , 103-108. | 0.1 | 0 |
| 329 | Potential effects of aliskiren on myocardial infarction on top of hypertension and heart failure in rats. <i>Benha Medical Journal</i> , 2018, 35, 163. | 0.0 | 0 |
| 331 | Management of Diabetic Nephropathy in the Elderly: Special Considerations. <i>Journal of Nephrology & Therapeutics</i> , 2012, 2, . | 0.1 | 1 |
| 332 | Managing hypertension in the elderly: a common chronic disease with increasing age. <i>American Health and Drug Benefits</i> , 2012, 5, 146-53. | 0.5 | 13 |
| 333 | Direct Renin Inhibitor Attenuates Left Ventricular Remodeling in Post-Myocardial Infarction Heart Failure Mice. <i>Acta Cardiologica Sinica</i> , 2013, 29, 160-7. | 0.1 | 3 |
| 334 | Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart Failure. <i>Kidney Medicine</i> , 2022, 4, 100465. | 1.0 | 4 |
| 335 | Screening for High Blood Pressure at the Dentistâ€™s Office. <i>Clinical, Cosmetic and Investigational Dentistry</i> , 2022, Volume 14, 79-85. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------|-----|-----------|
| 339 | Mathematical modeling of antihypertensive therapy. <i>Frontiers in Physiology</i> , 0, 13, . | 1.3 | 4 |
| 340 | Renin-“Angiotensin-“Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330. | | 1 |